Monday, January 26, 2009

Telcagepant & The Future of Migraine Prevention

New to Somebody Heal Me? Subscribe to the Somebody Heal Me feed:
Subscribe in a reader or subscribe by e-mail. Follow me on Twitter @somebodyhealme.

Research into the future of migraine abortives is focused on a category of drugs that target a substance released in the brain during a migraine attack called calcitonin gene-related peptide (CGRP).

One such drug, Telcagepant, is exciting to many doctors and patients because it promises a completely new method of aborting attacks. For people who cannot use triptans (such as Imitrex or Zomig) or who do not respond to them, the availability of this drug could be life changing.

The new drug is also exciting because testing demonstrates that patients experience fewer side effects with Telcagepant than with other medications.

James at the Headache & Migraine News Blog has written a thorough and informative article about Telcagepant:

What Everyone Should Know About Telcagepant

Rather than reinventing the wheel here, I would like to suggest you take a moment to read his excellent article to learn more about this medication.

Telcagepant is in Phase III of its clinical trials. Since data from this phase seems to indicate it is both effective and safe for patients, we can hope the drug will be available to the public sometime in the near future. It will depend on whether and when the FDA approves it.

Migraine Abortive Telcagepant Performs Well in Trials
Targeting Neuropeptides Could Be Future for Migraine Treatment

Related Posts:
Possible Genetic Explanation for Migraine
Migraine News Roundup 34

Technorati Tags: , , , , , , , , , ,

Subscribe to the Somebody Heal Me feed: Subscribe in a reader or subscribe by e-mail.

Photo Sharing and Video Hosting at Photobucket Content by Diana E. Lee.